Longitudinal Analysis of Peripheral Immune Cells in Patients with Multiple Sclerosis Treated with Anti-CD20 Therapy

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2024 Sep 16

PMID 39279291

Authors

Mie Waede

Lasse F Voss

Christina Kingo

Jesper B Moeller

Maria L Elkjaer

Zsolt Illes

Affiliations

Soon will be listed here.

Abstract

Objective: Anti-CD20 therapy is a highly effective treatment for multiple sclerosis (MS). In this study, we investigated MS-related changes in peripheral blood mononuclear cell (PBMC) subsets compared to healthy controls and longitudinal changes related to the treatment.

Methods: Multicolor spectral flow cytometry analysis was performed on 78 samples to characterize disease- and treatment-related PBMC clusters. Blood samples from MS patients were collected at baseline and up to 8 months post-treatment, with three collection points after treatment initiation. Unsupervised clustering tools and manual gating were applied to identify subclusters of interest and quantify changes.

Results: B cells were depleted from the periphery after anti-CD20 treatment as expected, and we observed an isolated acute, transitory drop in the proportion of natural killer (NK) and NKT cells among the main populations of PBMC (P = 0.03, P = 0.004). Major affected PBMC subpopulations were cytotoxic immune cells (NK, NKT, and CD8 T cells), and we observed a higher proportion of cytotoxic cells with reduced brain-homing ability and a higher regulatory function as a long-term anti-CD20-related effect. Additionally, anti-CD20 therapy altered distributions of memory CD8 T cells and reduced exhaustion markers in both CD4 and CD8 T cells.

Interpretation: The findings of this study elucidate phenotypic clusters of NK and CD8 T cells, which have previously been underexplored in the context of anti-CD20 therapy. Phenotypic modifications towards a more regulatory and controlled phenotype suggest that these subpopulations may play a critical and previously unrecognized role in mediating the therapeutic efficacy of anti-CD20 treatments.

References

Keir M, Liang S, Guleria I, Latchman Y, Qipo A, Albacker L . Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006; 203(4):883-95. PMC: 2118286. DOI: 10.1084/jem.20051776. View

El Mahdaoui S, Hansen M, von Essen M, Hvalkof V, Holm Hansen R, Mahler M . CD11c B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy. Ann Clin Transl Neurol. 2024; 11(4):926-937. PMC: 11021659. DOI: 10.1002/acn3.52009. View

Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung H, Montalban X . Role of B Cells in Multiple Sclerosis and Related Disorders. Ann Neurol. 2020; 89(1):13-23. PMC: 8007167. DOI: 10.1002/ana.25927. View

Li J, Zaslavsky M, Su Y, Guo J, Sikora M, van Unen V . KIRCD8 T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science. 2022; 376(6590):eabi9591. PMC: 8995031. DOI: 10.1126/science.abi9591. View

Deterre P, Berthelier V, Bauvois B, Dalloul A, Schuber F, Lund F . CD38 in T- and B-cell functions. Chem Immunol. 2000; 75:146-68. DOI: 10.1159/000058767. View

Sorensen T, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik V . Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999; 103(6):807-15. PMC: 408141. DOI: 10.1172/JCI5150. View

Van Gassen S, Callebaut B, van Helden M, Lambrecht B, Demeester P, Dhaene T . FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015; 87(7):636-45. DOI: 10.1002/cyto.a.22625. View

Abbadessa G, Miele G, Cavalla P, Valentino P, Marfia G, Signoriello E . CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab. Int J Environ Res Public Health. 2021; 18(15). PMC: 8346113. DOI: 10.3390/ijerph18158163. View

Ahmadi A, Fallah Vastani Z, Abounoori M, Azizi M, Labani-Motlagh A, Mami S . The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies. Health Sci Rep. 2022; 5(1):e489. PMC: 8865072. DOI: 10.1002/hsr2.489. View

10.

Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P . Human natural killer cells: origin, receptors, function, and clinical applications. Int Arch Allergy Immunol. 2014; 164(4):253-64. DOI: 10.1159/000365632. View

11.

Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil S . Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. Neurol Neuroimmunol Neuroinflamm. 2021; 8(1). PMC: 8063619. DOI: 10.1212/NXI.0000000000000918. View

12.

Feige J, Moser T, Akgun K, Schwenker K, Hitzl W, Haschke-Becher E . Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets. Ann Clin Transl Neurol. 2024; 11(2):450-465. PMC: 10863910. DOI: 10.1002/acn3.51965. View

13.

Gingele S, Jacobus T, Konen F, Hummert M, Suhs K, Schwenkenbecher P . Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients. Cells. 2019; 8(1). PMC: 6356421. DOI: 10.3390/cells8010012. View

14.

Mariottini A, Muraro P, Lunemann J . Antibody-mediated cell depletion therapies in multiple sclerosis. Front Immunol. 2022; 13:953649. PMC: 9511140. DOI: 10.3389/fimmu.2022.953649. View

15.

Landi D, Grimaldi A, Bovis F, Ponzano M, Fantozzi R, Buttari F . Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2022; 9(3). PMC: 9005049. DOI: 10.1212/NXI.0000000000001157. View

16.

Hamann I, Dorr J, Glumm R, Chanvillard C, Janssen A, Millward J . Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. J Neuroimmunol. 2012; 254(1-2):165-9. DOI: 10.1016/j.jneuroim.2012.08.009. View

17.

Kaur G, Trowsdale J, Fugger L . Natural killer cells and their receptors in multiple sclerosis. Brain. 2012; 136(Pt 9):2657-76. PMC: 3754456. DOI: 10.1093/brain/aws159. View

18.

Malavasi F, Funaro A, Alessio M, DeMonte L, Ausiello C, Dianzani U . CD38: a multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res. 1992; 22(2):73-80. DOI: 10.1007/BF02591400. View

19.

Karre K . Natural killer cell recognition of missing self. Nat Immunol. 2008; 9(5):477-80. DOI: 10.1038/ni0508-477. View

20.

Kivisakk P, Trebst C, Liu Z, Tucky B, Sorensen T, Rudick R . T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol. 2002; 129(3):510-8. PMC: 1906480. DOI: 10.1046/j.1365-2249.2002.01947.x. View